Close Window
Aetna Aetna
Clinical Policy Bulletin:
Hematopoietic Cell Transplantation for Aplastic Anemia and other Bone Marrow Failure Syndromes
Number: 0627


Policy

Aetna considers allogeneic hematopoietic cell transplantation medically necessary for the treatment of severe aplastic anemia, Diamond-Blackfan anemia, Fanconi's anemia, and paroxysmal nocturnal hemoglobinuria when members meet the transplanting institution's selection criteria. 

In the absence of a institution's selection criteria, Aetna considers allogeneic hematopoietic cell transplantation medically necessary for the treatment of severe aplastic anemia when the member has at least 3 of the 4 following features:

  • Bone marrow cellularity less than 25 % (markedly hypocellular)
  • Neutrophil count less than 0.5 x 109/L
  • Reticulocyte count less than 1 % or less than 20 x 109/L (corrected for hematocrit)
  • Untransfused platelet count less than 20 x 109/L

In the absence of an institution's selection criteria, Aetna considers allogeneic hematopoietic cell transplantation medically necessary for the treatment of Diamond-Blackfan anemia in persons who are refractory to corticosteroids.

In the absence of an institution's selection criteria, Aetna considers allogeneic hematopoietic cell transplantation medically necessary for Fanconi's anemia in persons with severe bone marrow failure, myelodysplastic syndrome, or acute myelogenous leukemia. 

In the absence of an institution's selection criteria, Aetna considers allogeneic hematopoietic cell transplantation medically necessary in persons with paroxysmal nocturnal hemoglobinuria with ongoing transfusion requirements and a suitable HLA-matched donor. 

Aetna considers autologous hematopoietic cell transplantation experimental and investigational for the treatment of severe aplastic anemia, Diamond-Blackfan anemia, Fanconi's anemia, and paroxysmal nocturnal hemoglobinuria because its effectiveness for these indications has not been established.



Background

Aplastic anemia (AA) is characterized by peripheral blood pancytopenia, resulting from a failure of the bone marrow to produce blood cells.  In the United States, it has an age-adjusted incidence of 2.2 per million populations per year.  Pathogenic mechanisms for AA vary and include intrinsic defects of hematopoietic stem cells, defects in the marrow micro-environment, and abnormal humoral or cellular immune control of hematopoiesis.  In most patients, AA is of unknown etiology (idiopathic), whereas in some, the disease can be secondary to infections, drugs or toxin exposure, and hereditary causes (e.g., Fanconi's anemia or Diamond-Blackfan syndrome).  Severe AA is defined by the presence of neutrophils less than 0.5 x 109/L, platelets less than 20 x 109/L, reticulocytes less than 1 %, and bone marrow cellularity less than 20 %.  When 3 of 4 of these symptoms are present, the median survival without therapy is about 3 months, with only 20 % of patients surviving for 12 months.  Currently, 2 definitive treatments are available for patients with severe AA: (i) immuno-suppressive therapy (IST) that includes the use of anti-thymocyte globulin, cyclosporine, and cyclophosphamide; and (ii) allogeneic bone marrow transplantation (ABMT).  The benefits of each are comparable.  However, certain subsets of patients derive superior benefit from one or the other.

Allogeneic bone marrow transplantation from human leukocyte antigen (HLA)-matched, related donors is generally accepted as the initial treatment of choice for young patients (less than 20 years old).  It results in the complete reconstitution of hematopoiesis, whereas autologous hematopoietic remissions after IST are more susceptible to relapse.  The literature indicates that survival rates after ABMT, in patients between the ages of 20 and 40, are comparable to those reported for IST.  Better survival rates after ABMT have been attained with improved conditioning regimens and graft-versus-host disease (GVHD) prophylaxis.  Best current results demonstrate long-term, event-free survivals with successful allografts on the order of 90 %.  Long-term complications after ABMT include GVHD and secondary neoplasms.  The role of ABMT from an unrelated donor is being investigated.

For patients older than 40, the generally accepted treatment of choice is IST, which entails the combination of anti-thymocyte globulin and cyclosporin A.  A variable proportion of patients (ranging from 20 to 80 %) respond to IST.  However, although responses may be frequent, long-term outcome is guarded because some patients may relapse and others may develop a clonal disorder, including myelodysplasia, leukemia, or paroxysmal nocturnal hemoglobinuria.  Long-term complications of IST include recurrence and development of clonal myeloid disorders.

In a review on ABMT for the treatment of AA, Horowitz (2000) stated that long-term survival rates ranged from less than 40 to more than 90 % in reported series.  These rates have improved over the past 20 years due to significant reductions in GVHD, interstitial pneumonitis, and early transplant-related mortality.  Most long-term survivors have excellent performance status.  Late complications such as cataracts, thyroid disorders, joint problems, and therapy-related cancers are observed, especially in patients who received radiation for pre-transplant conditioning.  Results are best in young patients transplanted with bone marrow from a HLA-identical sibling; early transplantation is appropriate in this group.  For older patients or those without an HLA-identical related donor, transplants are better reserved for those who fail to respond to IST.

Kojima and co-workers (2000a) compared the long-term outcome of acquired AA in children treated with IST or ABMT.  They recommended ABMT as first-line therapy in pediatric severe AA patients with an HLA-matched family donor.  Alternative donor ABMT was recommended as salvage therapy in patients who relapsed or did not respond to initial IST.  In a Consensus Conference on the Treatment of Aplastic Anemia, the participants recommended that the number of courses of IST for non-responders before unrelated ABMT consideration to be 1 for children and 2 for adults (Kojima et al, 2000b).

Bone marrow failure (BMF) syndromes entail a broad group of diseases of varying etiologies, in which hematopoeisis is abnormal or completely arrested in one or more cell lines.  Bone marrow failure syndromes can be an acquired AA or can be congenital, as part of such syndromes as Fanconi anemia (FA), Diamond Blackfan anemia (DBA), and Schwachman Diamond syndrome.  Hematopoietic bone marrow/stem cell transplantation is a therapeutic option for patients with BMF syndromes (Steele et al, 2006, Myers and Davies, 2009, Mehta et al, 2010).

In a report from the Aplastic Anemia Committee of the Japanese Society of Pediatric Hematology on hematopoietic stem cell transplantation (HSCT) for DBA, Mugishima et al (2007) stated that transfusion-dependent DBA patients opt for allogeneic HSCT as curative therapy.  These investigators analyzed clinical outcomes of 19 transplanted Japanese patients.  Prior to HSCT, 10 patients (53 %) suffered hemosiderosis with organ dysfunction, and all 8 with short stature (42 %) had adverse effects of prednisolone.  Median age at the time of HSCT was 56 months.  Transplantation sources were 13 bone marrow (6 HLA-matched siblings, and 6 HLA-matched and 1 HLA-mismatched unrelated donors), 5 cord blood (2 HLA-matched siblings and 3 HLA-mismatched unrelated donors), and 1 peripheral blood from haploidentical mother.  All 13 patients with BMT and 2 with sibling cord blood transplantation (CBT) had successful engraftment.  Of 3 patients who underwent unrelated CBT, 1 died after engraftment, and the other 2 had graft failure but succeeded in a second BMT from an HLA-disparate father and unrelated donor, respectively.  One died shortly after haploidentical PBSCT.  The 5-year failure-free survival rate after BMT was higher than CBT (100 %: 40 %, p = 0.002).  Platelet recovery was slower in 7 unrelated BMT than in 6 sibling BMT (p = 0.030).  No other factors were associated with engraftment and survival.  These results suggested that allogeneic BMT, but not unrelated CBT, is an effective HSCT for refractory DBA.

In a report from the Italian pediatric group, Locatelli and colleagues (2007) noted that HSCT represents the only treatment potentially able to prevent/rescue the development of marrow failure and myeloid malignancies in patients with FA.  While in the past HSCT from an HLA-identical sibling was proven to cure many patients, a higher incidence of treatment failure has been reported in recipients of an unrelated donor (UD) or HLA-partially matched related allograft.  These researchers analyzed the outcome of 64 FA patients (age range of 2 to 20 years) who underwent HSCT between January 1989 and December 2005.  Patients were transplanted from either an HLA-identical sibling (n = 31), an UD (n = 26), or an HLA-partially matched relative (n = 7).  T-cell depletion of the graft was performed in patients transplanted from an HLA-disparate relative.  The 8-year estimate of overall survival (OS) for the whole cohort was 67 %; it was 87 %, 40 % and 69 % when the donor was an HLA-identical sibling, an UD, and a mis-matched relative, respectively (p < 0.01).  The outcome of recipients of grafts from an UD improved over time, the probability of survival being 10 % and 72 % for patients transplanted before and after 1998, respectively (p < 0.05).  The OS probability of children who did or did not receive fludarabine in preparation for the allograft was 86 % and 59 %, respectively (p < 0.05).  These data provided support to the concept that a relevant proportion of FA patients undergoing HSCT can now be successfully cured, even in the absence of an HLA-identical sibling, especially if the conditioning regimen includes fludarabine.

Roth and colleagues (2009) stated that paroxysmal nocturnal hemoglobinuria (PNH) is characterized by the clinical triad of corpuscular hemolytic anemia, thrombophilia, and cytopenia.  This is caused by an acquired mutation of the PIG (phosphatidylinositol glycan)-A gene of the pluripotent hematopoetic stem cell.  This results in a deficiency of GPI (glycosylphosphatidylinositol)-anchors and GPI-anchored proteins on the surface of affected blood cells.  Flow cytometry is the standard for diagnosis and measurement of type and size of the PNH clone.  Treatment of PNH is mainly symptomatic.  Allogeneic BMT is the only curative option in case of severe complications during the course of the diseases.

Li and colleagues (2013) noted that although high-dose cyclophosphamide seems to achieve durable complete remission, there are still concerns about its too much early toxicity.  Thus, these researchers designed a clinical study to examine the effects of high-dose cyclophosphamide/anti-thymocyte globulin (ATG) combined with cord blood infusion as first-line therapy for patients with severe AA.  Between January 2003 and September 2007, these investigators treated 16 treatment-naive patients with severe AA with cord blood infusion after high-dose cyclophosphamide (50 mg/kg/day × 2) and rabbit ATG (3 mg/kg/day × 5) therapy.  Although only 1 patient had durable full donor engraftment, 14 of the enrolled 16 patients had rapid autologous hematopoietic recovery.  The median recovery time for neutrophils and platelets was only 23 and 37 days after infusion of cord blood.  Of the 15 responding patients, all patients achieved treatment-free remission: 9 patients met the criteria for a complete remission; 6 patients achieved a partial remission.  The authors concluded that infusion of cord blood after high-dose cyclophosphamide/ATG resulted in a rapid autologous hematologic recovery and a high response rate in patients with treatment-naive patients with severe AA.  They stated that these promising results merit further investigation and confirmation on a larger number of patients.

An UpToDate review on “Aplastic anemia: Prognosis and treatment” (Schrier, 2013) states that “Only a fraction of patients with severe aplastic anemia in first or second complete remission are able to mobilize sufficient stem cells to undergo autologous hematopoietic cell transplantation (HCT).  Accordingly, patients with relapsing or resistant disease, who have even fewer mobilizable stem cells than those in remission, are not candidates for autologous HCT”.  Furthermore, an UpToDate review on “Hematopoietic cell transplantation in aplastic anemia” (Negrin, 2013) recommends the use of allogeneic HCT; it does not mention the use of autologous HCT as a therapeutic option.

UpToDate reviews on “Hematopoietic cell transplantation for Diamond-Blackfan anemia and the myelodysplastic syndromes in children” (Khan, 2013) and “Hematopoietic cell transplantation for idiopathic severe aplastic anemia and Fanconi anemia in children” (Khan and Negrin, 2013) do not mention the use of autologous HCT as a therapeutic option.

An UpToDate review on “Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria” (Rosse, 2013) states that “autologous transplantation is unlikely to be successful because of the difficulty in obtaining sufficient numbers of normal stem cells”.

 
CPT Codes / HCPCS Codes / ICD-9 Codes
Transplantation - Allogeneic:
CPT codes covered if selection criteria are met:
38230
38240
86813
86817
86821
86822
Other CPT codes related to the CPB:
38204 - 38215
85004 - 85049
85055
85060
85097
86920 - 86923
Modifiers 4A - 4Z
HCPCS codes covered if selection criteria are met:
S2150 Bone marrow or blood-derived stem-cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre- and post-transplant care in the global definition
ICD-9 codes covered if selection criteria are met:
283.2 Hemoglobinuria due to hemolysis from external causes [paroxysmal nocturnal hemoglobinuria]
284.01 - 284.9 Aplastic anemia [severe]
Transplantation - Autologous:
CPT codes not covered for indications listed in the CPB:
38323
38241


The above policy is based on the following references:
  1. Fonseca R, Tefferi A. Practical aspects in the diagnosis and management of aplastic anemia. Am J Med Sci. 1997;313(3):159-169.
  2. Storb R. Aplastic anemia. J Intraven Nurs. 1997;20(6):317-322.
  3. Guinan EC. Clinical aspects of aplastic anemia. Hematol Oncol Clin North Am. 1997;11(6):1025-1044.
  4. Horowitz MM. Current status of allogeneic bone marrow transplantation in acquired aplastic anemia. Semin Hematol. 2000;37(1):30-42.
  5. Bacigalupo A, Brand R, Oneto R, et al. Treatment of acquired severe aplastic anemia: Bone marrow transplantation compared with immunosuppressive therapy -- The European Group for Blood and Marrow Transplantation experience. Semin Hematol. 2000;37(1):69-80.
  6. Socie G, Gluckman E. Cure from severe aplastic anemia in vivo and late effects. Acta Haematol. 2000;103(1):49-54 .
  7. Killick SB, Marsh JC. Aplastic anaemia: Management. Blood Rev. 2000;14(3):157-171.
  8. Kojima S, Horibe K, Inaba J, et al. Long-term outcome of acquired aplastic anaemia in children: Comparison between immunosuppressive therapy and bone marrow transplantation. Br J Haematol. 2000a;111(1):321-328.
  9. Kojima S, Nakao S, Tomonaga M, et al. Consensus Conference on the Treatment of Aplastic Anemia. Int J Hematol. 2000b;72(1):118-123.
  10. Linker CA. Anemias. In: Current Medical Diagnosis & Treatment 2001. 40th Ed, LM Tierney Jr, et al. eds. New York, NY: Lange Medical Books/McGraw-Hill; 2001; Ch. 13:505-558.
  11. Young NS. Acquired aplastic anemia. Ann Intern Med. 2002;136(7):534-546.
  12. Abdelkefi A, Ben Othman T, Ladeb S, et al. Bone marrow transplantation for patients with acquired severe aplastic anemia using cyclophosphamide and antithymocyte globulin: The experience from a single center. Hematol J. 2003;4(3):208-213.
  13. Kim HJ, Park CY, Park YH, et al. Successful allogeneic hematopoietic stem cell transplantation using triple agent immunosuppression in severe aplastic anemia patients. Bone Marrow Transplant. 2003;31(2):79-86.
  14. Geissler K. Pathophysiology and treatment of aplastic anemia. Wien Klin Wochenschr. 2003;115(13-14):444-450.
  15. Brodsky RA, Jones RJ. Aplastic anaemia. Lancet. 2005;365(9471):1647-1656. 
  16. Rzepecki P, Sarosiek T, Szczylik C. Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience. Jpn J Clin Oncol. 2006 ;36(1):46-49.
  17. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108(8):2509-2519. 
  18. Champlin RE, Perez WS, Passweg JR, et al. Bone marrow transplantation for severe aplastic anemia: A randomized controlled study of conditioning regimens. Blood. 2007;109(10):4582-4585.
  19. Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Stem cell transplantation in acquired severe aplastic anaemia. Summary. Report N05-03B.Cologne, Germany: IQWiG; 2007.
  20. Perez-Albuerne ED, Eapen M, Klein J, et al. Outcome of unrelated donor stem cell transplantation for children with severe aplastic anemia. Br J Haematol. 2008;141(2):216-223.
  21. Young NS, Scheinberg P, Calado RT. Aplastic anemia. Curr Opin Hematol. 2008;15(3):162-168.
  22. Bacigalupo A. Treatment strategies for patients with severe aplastic anemia. Bone Marrow Transplant. 2008;42 Suppl 1:S42-S44.
  23. Yoshimi A, Kojima S, Taniguchi S, et al. Unrelated cord blood transplantation for severe aplastic anemia. Biol Blood Marrow Transplant. 2008;14(9):1057-1063.
  24. Chan KW, McDonald L, Lim D, et al. Unrelated cord blood transplantation in children with idiopathic severe aplastic anemia. Bone Marrow Transplant. 2008;42(9):589-595.
  25. Ohga S, Mugishima H, Ohara A, et al; Aplastic Anemia Committee Japanese Society of Pediatric Hematology. Diamond-Blackfan anemia in Japan: Clinical outcomes of prednisolone therapy and hematopoietic stem cell transplantation. Int J Hematol. 2004;79(1):22-30.
  26. Guardiola P, Socie G, Li X, et al. Acute graft-versus-host disease in patients with Fanconi anemia or acquired aplastic anemia undergoing bone marrow transplantation from HLA-identical sibling donors: Risk factors and influence on outcome. Blood. 2004;103(1):73-77.
  27. Steele JM, Sung L, Klaassen R, et al; Canadian Inherited Marrow Failure Registry. Disease progression in recently diagnosed patients with inherited marrow failure syndromes: A Canadian Inherited Marrow Failure Registry (CIMFR) report. Pediatr Blood Cancer. 2006;47(7):918-925.
  28. Bitan M, Or R, Shapira MY, et al. Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors. Biol Blood Marrow Transplant. 2006;12(7):712-718.
  29. Tan PL. Wagner JE, Auerbach AD, et al. Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation. Pediatr Blood Cancer. 2006;46(5):630-636.
  30. Mugishima H, Ohga S, Ohara A, et al; for the Aplastic Anemia Committee of the Japanese Society of Pediatric Hematology. Hematopoietic stem cell transplantation for Diamond-Blackfan anemia: A report from the Aplastic Anemia Committee of the Japanese Society of Pediatric Hematology. Pediatr Transplant. 2007;11(6):601-6077.
  31. Locatelli F, Zecca M, Pession A, et al; Italian pediatric group. The outcome of children with Fanconi anemia given hematopoietic stem cell transplantation and the influence of fludarabine in the conditioning regimen: A report from the Italian pediatric group. Haematologica. 2007;92(10):1381-1388.
  32. Chaudhury S, Auerbach AD, Kernan NA, et al. Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia. Br J Haematol. 2008;140(6):644-655.
  33. Maury S, Bacigalupo A, Anderlini P, et al; Severe Aplastic Anemia Working Party, European Group for Blood and Marrow Transplantation (EBMT-SAAWP). Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: A comparison with conventional conditioning regimen. Haematologica. 2009;94(9):1312-1315.
  34. Peinemann F, Grouven U, Kröger N, et al. Unrelated donor stem cell transplantation in acquired severe aplastic anemia: A systematic review. Haematologica. 2009;94(12):1732-1742.
  35. Marsh JC, Ball SE, Cavenagh J, et al; British Committee for Standards in Haematology. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147(1):43-70.
  36. Green AM, Kupfer GM. Fanconi anemia. Hematol Oncol Clin North Am. 2009;23(2):193-214.
  37. Röth A, Dührsen U, Schrezenmeier H, Schubert J. Paroxysmal nocturnal hemoglobinuria (PNH). Pathogenesis, diagnosis and treatment. Dtsch Med Wochenschr. 2009;134(9):404-409.
  38. Matos-Fernandez NA, Abou Mourad YR, Caceres W, Kharfan-Dabaja MA. Current status of allogeneic hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria. Biol Blood Marrow Transplant. 2009;15(6):656-661.
  39. MacMillan ML, Wagner JE. Haematopoeitic cell transplantation for Fanconi anaemia -- when and how? Br J Haematol. 2010;149(1):14-21.
  40. Myers KC, Davies SM. Hematopoietic stem cell transplantation for bone marrow failure syndromes in children. Biol Blood Marrow Transplant. 2009;15(3):279-292.
  41. Lipton JM, Ellis SR. Diamond-Blackfan anemia: Diagnosis, treatment, and molecular pathogenesis. Hematol Oncol Clin North Am. 2009;23(2):261-282.
  42. Leblanc T. Blackfan-Diamond disease. Orphanet. Paris, France: Orphanet/INSERM; February 2009.
  43. Mehta P, Locatelli F, Stary J, Smith FO. Bone marrow transplantation for inherited bone marrow failure syndromes. Pediatr Clin North Am. 2010;57(1):147-170.
  44. Alter BP, Giri N, Savage SA, et al. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol. 2010;150(2):179-188.
  45. Bizzetto R, Bonfim C, Rocha V, et al; Eurocord and SAA-WP from EBMT. Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia. Haematologica. 2011;96(1):134-141.
  46. Peinemann F, Grouven U, Kroger N, et al. First-line matched related donor hematopoietic stem cell transplantation compared to immunosuppressive therapy in acquired severe aplastic anemia. PLoS One. 2011;6(4):e18572.
  47. Li Y, Sheng Z, Niu S, et al. Rapid and complete reconstitution of autologous haemopoiesis after cord blood infusion in treatment-naive patients with severe aplastic anemia receiving high-dose cyclophosphamide/ATG therapy. Eur J Haematol. 2013;90(1):45-50.
  48. Schrier SL. Aplastic anemia: Prognosis and treatment. Last reviewed May 2013. UpToDate Inc., Waltham, MA.
  49. Negrin RS. Hematopoietic cell transplantation in aplastic anemia. Last reviewed May 2013. UpToDate Inc., Waltham, MA.
  50. Khan S. Hematopoietic cell transplantation for Diamond-Blackfan anemia and the myelodysplastic syndromes in children. Last reviewed May 2013. UpToDate Inc., Waltham, MA.
  51. Khan S, Negrin RS. Hematopoietic cell transplantation for idiopathic severe aplastic anemia and Fanconi anemia in children. Last reviewed May 2013. UpToDate Inc., Waltham, MA.
  52. Rosse WF. Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria. Last reviewed May 2013. UpToDate Inc., Waltham, MA.


email this page   


Copyright Aetna Inc. All rights reserved. Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.
Aetna
Back to top